Group One Trading, L.P. Albireo Pharma, Inc. Transaction History

Group One Trading, L.P.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$18.01 - $23.78 $12,462 - $16,455	692 Added 854.32%	773 $16,000
Q3 2022 Nov 09, 2022	SELL	$16.32 - $26.37 $3,264 - $5,274	-200 Reduced 71.17%	81 $2,000
Q2 2022 Aug 11, 2022	BUY	$18.54 - $37.29 $166 - $335	9 Added 3.31%	281 $6,000
Q1 2022 May 12, 2022	SELL	$23.94 - $33.74 $51,207 - $72,169	-2,139 Reduced 88.72%	272 $8,000
Q4 2021 Feb 11, 2022	SELL	$21.19 - $31.29 $135,298 - $199,786	-6,385 Reduced 72.59%	2,411 $56,000
Q3 2021 Nov 12, 2021	BUY	$27.36 - $35.98 $37,948 - $49,904	1,387 Added 18.72%	8,796 $274,000
Q2 2021 Aug 10, 2021	BUY	$28.9 - $36.87 $53,262 - $67,951	1,843 Added 33.11%	7,409 $261,000
Q1 2021 May 12, 2021	SELL	$32.03 - $42.85 $277,091 - $370,695	-8,651 Reduced 60.85%	5,566 $196,000
Q4 2020 Feb 10, 2021	SELL	$31.56 - $42.16 $755,262 - $1.01 Million	-23,931 Reduced 62.73%	14,217 $533,000
Q3 2020 Nov 12, 2020	BUY	$23.19 - $41.61 $884,652 - $1.59 Million	38,148 New	38,148 $1.27 Million
Q1 2019 May 13, 2019	SELL	$22.22 - $32.21 $44 - $64	-2 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	2	2 $0

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.